Rapid exponential elimination of free prostate-specific antigen contrasts the slow, capacity-limited elimination of PSA complexed to alpha1- antichymotrypsin from serum

Urology

Volumn 51, Issue 1, 1998, Pages 57-62

  Björk, Thomas ^a   Ljungberg, Bengt ^a   Piironen, Timo ^b   Abrahamsson, Per Anders ^a   Pettersson, Kim ^b   Cockett, Abraham T K ^c   Lilja, Hans ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF TURKU   (Finland)

^c STRONG MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; GLOMERULUS FILTRATION; HUMAN; IMMUNOFLUORESCENCE TEST; KIDNEY CLEARANCE; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN TRANSPORT;

AGED; ALPHA 1-ANTICHYMOTRYPSIN; HUMANS; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; TIME FACTORS;

EID: 0031891632     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(97)00572-4     Document Type: Article

References (27)

1. Nadler RB, Humphrey PA, Smith DS, Catalona WJ, Ratliff TL. Effects of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol. 154:1995;407-413.
2. Yuan JJJ, Coplen DE, Petros JA, Figenshau RS, Ratliff TL, Smith DS, Catalona WJ. Effects of rectal examination, prostatic massage, ultrasonography and needle biopsy on serum prostate specific antigen levels. J Urol. 147:1995;810-814.
3. Vesey SG, Goble NM, Stower MJ, Hammonds JC, Smith JB. The effects of transurethral prostatectomy on serum prostate specific antigen. Br J Urol. 62:1988;347-351.
4. Montgomery BT, Young CY, Bilhartz DL, Andrews PE, Prescott JL, Thompson NF, Tindall DJ. Hormonal regulation of prostate-specific antigen (PSA) glycoprotein in the human prostatic adenocarcinoma cell line. Prostate. 21:1992;63-73.
5. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 317:1987;909-916.
6. Oesterling JE, Chan DW, Epstein JI, Kimball AW, Bruzek DJ, Rock RC, Brendler CB, Walsh PC. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol. 139:1988;766-772.
7. Christensson A, Laurell C-B, Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine protease inhibitors. Eur J Biochem. 194:1990;755-763.
8. Pettersson K, Piironen T, Seppälä M, Liukkonen L, Christensson A, Matikainen MJ, Suonpää M, Lövgren T, Lilja H. Free and complexed prostate-specific antigen (PSA) in vitro stability, epitope map, and development of immunofluorometric assays for specific and sensitive detection of free PSA and PSA-alpha-1-antichymotrypsin complex . Clin Chem. 41:1995;1480-1488.
9. Jacobsen SJ, Lilja H, Klee GG, Wright GL Jr, Pettersson K, Oesterling JE. Comparability of the Tandem-R and IMx assays for the measurement of serum prostate-specific antigen. Urology. 44:1994;512-518.
10. Lilja H, Christensson A, Dahlén U, Matikainen MJ, Nilsson O, Pettersson K, Lövgren T. Prostate-specific antigen in serum occurs predominantly in complex with alpha-1-antichymotrypsin. Clin Chem. 37:1991;1618-1625.
11. Gibaldi M: Biopharmaceutics and Clinical Pharmacokinetics, 4th ed. Philadelphia, Lea & Febiger, 1991.
12. Becker C, Piironen T, Pettersson K, Björk T, Wojno KJ, Oesterling JE, Lilja H. Clinical utility of a novel, highly sensitive and specific assay for human glandular kallikrein (hK2) in serum (abstract). J Urol. 157:1997;1722.
13. Leinonen J, Zhang WM, Stenman UH. Complex formation between PSA isoenzymes and protease inhibitors. J Urol. 155:1996;1099-1103.
14. Piironen T, Pettersson K, Suonpää M, Stenman UH, Oesterling JE, Lövgren T, Lilja H. In vitro stability of free PSA and PSA complexed to alpha-1-antichymotrypsin in blood samples. Urology. 48:(suppl 6A):1996;81-87.
15. Chen Z, Komatzu K, Prestigiacomo A, Stamey TA. Addition of purified prostate specific antigen to serum from female subjects studies on the relative inhibition by alpha-2-macroglobulin and alpha-1-antichymotrypsin . J Urol. 156:1996;1357-1363.
16. Björk T, Abrahamsson PA, Lilja H, Pettersson K, Cockett ATK. Rates of clearance of free and complexed forms of PSA in serum after radical prostatectomy and transurethral thermotherapy (abstract). J Urol. 153:1995;265.
17. Björk T, Abrahamsson PA, Lilja H. The effects of physical activity on serum PSA forms and ratios (abstract). J Urol. 157:1997;440.
18. Ornstein DK, Rao GS, Smith DS, Ratliff TL, Basler JW, Catalona WJ. Effect of digital rectal examination and needle biopsy on serum total and percentage of free prostatic specific antigen levels. J Urol. 157:1997;195-198.
19. Kabalin JN, Hornberger JC. Prostate-specific antigen is not excreted by human kidney or eliminated by routine hemodialysis. Urology. 37:1991;308-310.
20. Mast AE, Enghild JJ, Pizzo SV, Salvesen G. Analysis of the plasma elimination kinetics and conformational stabilities of native, proteinase-complexed, and reactive site cleaved serpins comparison of alpha 1-proteinase inhibitor, alpha 1-antichymotrypsin, anthitrombin III, alpha 2-antiplasmin, angiotensinogen, and ovalubumin . Biochemistry. 30:1991;1723-1730.
21. Perlmutter DH, Glover GI, Rietvna M, Schastens CS, Fallon RJ. Identification of a serpin-enzyme complex receptor on human hepatoma cells and human monocytes. Proc Natl Acad Sci USA. 87:1990;3753-3757.
22. Haab F, Meulemans A, Dauge MC, Delmas V, Boccon-Gibod L. Clearance of serum PSA after open surgery for benign prostatic hypertrophy, radical cystectomy, and radical prostatectomy. Prostate. 26:1995;334-338.
23. Semjonow A, Hamm M, Rathert P, Hertle L. Half-life of prostate specific antigen (abstract). J Urol. 151:1994;449.
24. Brändle E, Gottfried HW, Maier S, Kleinschmidt K, Hautmann RE. Clearance of PSA after radical prostatectomy - a suitable model for calculation of PSA half-life. J Urol. 153:(abstract):1996;1107.
25. Richardson TD, Wojno KJ, Liang LW, Giacherio DA, England BG, Henricks WH, Schork A, Oesterling JE. Half-life determinations of serum free prostate-specific antigen following radical retropubic prostatectomy. Urology. 48:(suppl 6A):1996;40-44.
26. Partin AW, Piantadosi S, Subong ENP, Kelly CA, Hortopan S, Chan DW, Wolfert RL, Rittenhouse HG, Carter HB. Clearance rate of serum-free and total PSA following radical retropubic prostatectomy. Prostate. 7:(suppl):1996;535-539.
27. Gleave ME, Goldenberg SL, Jones EC, Bruchovsky N, Kinahan J, Sullivan LD. Optimal duration of neoadjuvant androgen withdrawal therapy before radical prostatectomy in clinically confined prostate cancer. Semin Urol Oncol. 14:(suppl):1996;39-45.